The present invention is directed to compounds of generic formula I: or pharmaceutically acceptable salts thereof that are believed to be useful as an A2A-receptor antagonist.
本发明涉及通式 I:的化合物或其药学上可接受的盐类,这些化合物被认为可用作 A2A 受体拮抗剂。
AMINOQUINAZOLINE COMPOUNDS AS A2A ANTAGONIST
申请人:Merck Sharp & Dohme Corp.
公开号:US20180037554A1
公开(公告)日:2018-02-08
The present invention is directed to compounds of generic formula I: or pharmaceutically acceptable salts thereof that are believed to be useful as an A2A-receptor antagonist.